for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

131.33USD

Change

2.27(+1.76%)

Volume

2,147,310

Today's Range

130.86

 - 

132.61

52 Week Range

122.00

 - 

148.97

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
129.06
Open
131.14
Volume
2,147,310
3M AVG Volume
157.82
Today's High
132.61
Today's Low
130.86
52 Week High
148.97
52 Week Low
122.00
Shares Out (MIL)
2,639.17
Market Cap (MIL)
346,601.60
Forward P/E
15.27
Dividend (Yield %)
2.89

Next Event

Q3 2019 Johnson & Johnson Earnings Release

Latest Developments

More

Johnson's Baby Powder Was Not The Cause Of California Plaintiff's Disease, says J&J Spokesman

Amneal Announces Launch Of Generic Invega

J&J Says Ronald Kapusta, Controller & Chief Accounting Officer, To Retire, Effective Dec 27, 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.16 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

71.9K

2017

76.5K

2018

81.6K

2019(E)

81.5K
EPS (USD)

2016

6.730

2017

7.300

2018

8.180

2019(E)

8.602
Price To Earnings (TTM)
21.78
Price To Sales (TTM)
4.26
Price To Book (MRQ)
5.71
Price To Cash Flow (TTM)
14.90
Total Debt To Equity (MRQ)
48.40
LT Debt To Equity (MRQ)
45.57
Return on Investment (TTM)
12.98
Return on Equity (TTM)
10.52

Latest News

Latest News

Massive jury award against J&J highlights risks of its legal strategy

A jury award that hit Johnson & Johnson <JNJ.N> with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday.

Johnson & Johnson hit as jury awards "excessive" $8 bln in damages

Shares of Johnson & Johnson dipped 2% on Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts.

Jury says J&J must pay $8 billion in case over male breast growth linked to Risperdal

Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

Oklahoma appeals size of $572 million award in J&J opioid case

Oklahoma's attorney general has moved to appeal a judge's ruling holding that state had only established it was entitled to just $572 million of the $17 billion it requested on its claims that Johnson & Johnson fueled the opioid epidemic through deceptive painkiller marketing...

J&J's Acclarent must face whistleblower's wrongful discharge claim at trial - judge

A federal judge has cleared the way for an ex-Acclarent Inc sales representative to take the Johnson & Johnson unit to trial over her claim it wrongfully fired her because she refused to promote a medical device for unapproved uses.

Johnson & Johnson settles Ohio lawsuits to avoid federal trial

Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation's opioid epidemic.

UPDATE 2-Johnson & Johnson settles Ohio lawsuits to avoid federal trial

Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation's opioid epidemic.

J&J settles with Ohio counties ahead of opioid trial

Johnson & Johnson said on Tuesday it settled with two Ohio counties, ahead of an opioid trial scheduled to begin on Oct. 21.

Drugmakers look to use Purdue Pharma's bankruptcy to settle U.S. opioid suits: WSJ

Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...

Drugmakers look to use Purdue Pharma's bankruptcy to settle opioid suits -WSJ

Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...

3rd Circuit orders Remicade antitrust lawsuit to arbitration

A drug wholesaler must submit its claims that Johnson & Johnson is illegally suppressing competition for its rheumatoid arthritis treatment Remicade to an arbitrator, a federal appeals court held on Friday.

Bayer hires former J&J executive for more pharma deals

Bayer <BAYGn.DE> said it hired Johnson & Johnson <JNJ.N> executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.

US STOCKS-Wall Street dips as financials weigh, trade hopes dim

* Dow down 0.35%, S&P 500 down 0.28%, Nasdaq down 0.39% (Updates to mid-afternoon, changes byline)

US STOCKS-Wall Street treads water as financials fall, trade hopes flicker

* Indexes: Dow & S&P 500 flat, Nasdaq off 0.04% (Updates prices, comments)

J&J liable for $572 million in Oklahoma opioid epidemic trial; shares rise

An Oklahoma judge on Monday ordered Johnson & Johnson <JNJ.N> to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum that was substantially less than investors had expected, driving up J&J's shares.

EXPLAINER: Oklahoma judge weighs if J&J created opioid public nuisance

A lawsuit by Oklahoma's attorney general accusing Johnson & Johnson of fueling the opioid epidemic is set to establish a major precedent over whether a state's public nuisance laws can be used to hold a drugmaker liable for the U.S. drug crisis.

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Oklahoma makes final bid to hold J&J responsible for opioid epidemic

Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...

J&J warns of hit from generic drugs in third quarter, shares fall

Johnson & Johnson <JNJ.N> on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up